Terns Pharmaceuticals' SWOT analysis: promising pipeline drives stock potential

Terns Pharmaceuticals (TERN) is advancing its pipeline with TERN-701 for CML, showing promising early Phase 1 data regarding safety and efficacy in heavily pre-treated patients, and TERN-601, an oral GLP-1RA for obesity, with a Phase 2 trial planned for Q2 2025. The company's strong cash position of $334.3 million, expected to fund operations into 2028, supports these clinical programs, while analysts maintain bullish price targets despite the stock's recent volatility and a competitive market landscape in both CML and obesity treatments.

Analysis

Terns Pharmaceuticals (NASDAQ:TERN) is advancing a focused pipeline with two key clinical-stage assets: TERN-701 for chronic myeloid leukemia (CML) and TERN-601 for obesity, both of which have shown encouraging early-stage results. TERN-701, an oral BCR-ABL tyrosine kinase inhibitor, demonstrated a favorable safety profile in its Phase 1 CARDINAL study, with all hematologic treatment-related adverse events reported as grade 1 or 2 in heavily pre-treated CML patients, where 80% of 15 evaluable subjects had received three or more prior TKIs; further efficacy data is anticipated in H1 2025. Concurrently, TERN-601, an oral GLP-1 receptor agonist, is set to enter a Phase 2 study (FALCON) in Q2 2025, aiming to capitalize on the growing demand for oral obesity treatments, a market segment buoyed by positive developments such as Eli Lilly's orforglipron. Financially, TERN reported a robust cash position of $334.3 million as of March 31, 2025, projected to fund operations into 2028, although the company is experiencing significant cash burn with a negative free cash flow of $71.7 million in the last twelve months. Despite the stock's substantial decline of nearly 49% over the past six months to $3.02, an InvestingPro Fair Value model suggests potential undervaluation, and analyst price targets remain bullish, ranging from $14 to $34. Key risks include the early stage of clinical data, reliance on these two candidates, and intense competition in both therapeutic areas; however, the stock's low beta of -0.17 may offer diversification benefits.

Key Decisions for Investors

• Investors should weigh the speculative nature of TERN, driven by its early-stage assets and recent stock underperformance, against the potential upside indicated by analyst targets and undervaluation metrics, recognizing the binary risk associated with clinical trial outcomes.
• Closely monitor key upcoming catalysts, particularly the more comprehensive TERN-701 CML data expected in H1 2025 and the initiation and early signals from the TERN-601 Phase 2 FALCON study for obesity in Q2 2025, as these will be critical inflection points for the company.
• Assess TERN's financial runway, supported by $334.3 million in cash, in the context of its $71.7 million annual cash burn rate, and consider the competitive positioning of TERN-701's safety profile and TERN-601's oral formulation against established and emerging therapies in their respective CML and obesity markets.